Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Glaucoma combo solution earns preliminary approval
The FDA has issued an approvable letter for the fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution (Extravan) for the treatment of glaucoma, according to Alcon Laboratories, its manufacturer.
The FDA has issued an approvable letter for the fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution (Extravan) for the treatment of glaucoma, according to Alcon Laboratories, its manufacturer.
The company said it would meet with the FDA to clarify what steps are yet required to gain final marketing approval.
Related Videos
Related Content
